Source: Fox News
Summary
The FDA has approved a new gene therapy, Otarmeni, for the treatment of genetic hearing loss caused by the OTOF gene. This therapy is the first dual adeno-associated virus (AAV) vector-based gene therapy and has shown positive results in clinical trials. The treatment is administered surgically and works by delivering a healthy copy of the OTOF gene to key cells in the inner ear. The FDA has called the therapy “groundbreaking” and noted its potential to treat both pediatric and adult patients with severe to profound hearing loss.
Our Reading
The advice sounds familiar.
The use of gene therapy to treat genetic disorders has been a topic of interest for several years, with various studies and trials underway. The approval of Otarmeni marks a significant milestone in the treatment of genetic hearing loss. The fact that this therapy is administered surgically and uses a dual-vector approach is a notable development. The FDA’s National Priority Voucher (CNPV) pilot program has played a role in accelerating the approval of this therapy. As with any new treatment, it will be important to monitor the long-term effects and outcomes of Otarmeni.
The treatment of genetic hearing loss has entered another phase.
Author: Evan Null
